Enveric Biosciences Inc (ENVB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.45M
Last updated: Nov 17, 2026 at 4:10 PM ET
Enveric Biosciences Inc (ENVB) Statistics
Enveric Biosciences (ENVB) has a market cap of $6.45M and an enterprise value of $832.31K. It holds $5.61M more cash than debt, 87.09% of its market cap.
Total Valuation
Enterprise value is 87.09% below the market cap, as cash exceeds debt.
| Market Cap | $6.45M |
|---|---|
| Enterprise Value | $832.31K |
| Latest price (Nov 17, 2026) | $1.41 |
Key Dates
The next earnings report is expected on Mar 25, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 25, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.2x and 1.1x.
| P/S Ratio | 0.2x |
|---|---|
| P/B Ratio | 1.1x |
Price Statistics
The stock is down 73.30% over 52 weeks and trades 4.08% below its 50-day average.
| Beta (1Y) | 0.77 |
|---|---|
| 52-Week Change | -73.30% |
| 1-Month Change | +1.44% |
| 3-Month Change | +7.63% |
| 6-Month Change | -33.18% |
| 5-Year Change | -99.99% |
| Total Return (1Y) | -73.30% |
| Total Return (3Y CAGR) | -82.64% |
| Total Return (5Y CAGR) | -84.28% |
| Return vs SPY (1Y) | -86.69% |
| Max Drawdown (1Y) | -87.71% |
| Max Drawdown (3Y) | -99.58% |
| Sharpe Ratio (1Y) | -0.99 |
| Correlation with SPY (1Y) | 0.08 |
| 50-Day Average | $1.47 |
| 200-Day Average | $1.88 |
| 52-Week Range | $1.17 to $13.25 |
| RSI (14 Days) | 45.0 |
| Average Volume (20 Days) | 31.39K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.70x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 9.70x |
|---|---|
| Quick Ratio | 9.70x |
| Debt / Equity | 0.00x |
| Interest Coverage | -7800.00x |
Returns and Efficiency
| Return on Assets (ROA) | -137.00% |
|---|---|
| Receivables Turnover | 4720.68x |
Scores
ENVB has an Altman Z-Score of -18.84, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -18.84 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Balance Sheet
| Cash and Equivalents | $5.61M |
|---|---|
| Total Debt | $0 |
| Net Cash | $5.61M |
| Net Cash Per Share | $1.25 |
Balance sheet as of Sep 30, 2026.
Dividends and Yields
ENVB does not pay a dividend. Its free cash flow yield is -144.53%.
| FCF Yield | -144.53% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-12 reverse split on Oct 28, 2025.
| Last Split Date | Oct 28, 2025 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ENVB
What is ENVB's market cap?
Enveric Biosciences has a market cap of $6.45M. Its enterprise value, which adds debt and subtracts cash, is $832.31K.
How many shares of ENVB are outstanding?
Enveric Biosciences has 4.48M shares outstanding.
Does ENVB pay a dividend?
No. Enveric Biosciences does not pay a dividend.
How much debt does ENVB have?
Enveric Biosciences has $0 of total debt and $5.61M of cash and equivalents, a net cash position of $5.61M.
ENVB pages: Overview, Charting, Earnings, Financials, Statistics, Competitors